Key Summary
- The profit before tax in 2025 increased to £144.1 million, up from £136.8m in 2024, a rise of 5.3 percent.
- Superdrug increased its healthcare offering through professionally led Health Clinics and healthcare ambassadors.
- In 2025, it provided over 45,000 Pharmacy First consultations, and this also boosted the company's pharmacy performance.
Despite a bleak UK retail market, health and beauty retailer Superdrug Stores Plc delivered strong financial performance in 2025, registering overall growth across its retail stores and online channels.
The profit before tax in 2025 increased to £144.1 million, up from £136.8m in 2024, a rise of 5.3 percent, primarily driven by the strong sales performance, the retailer stated in its Companies House filing.
Superdrug registered a 5.2 percent increase in sales, and its revenue rose to £1.71 billion, up from £1.3bn in 2024.
Superdrug continued to expand its healthcare offering through professionally led Health Clinics and healthcare ambassadors.
It provided personalised support and clinically approved weight-management treatments delivered by trained nurses and pharmacists.
During the year, the NHS Pharmacy First service continued to gain traction and delivered strong patient uptake.
In 2025, it provided over 45,000 Pharmacy First consultations, which helped increase patient access to primary care while supporting the company's pharmacy performance.
The retailer continued to invest in its estate, including the opening of 22 new stores in 2025 (13 in 2024) and the ongoing refurbishment of existing stores.
Superdrug's continued focus on productivity and cost efficiency, combined with the increase in sales, contributed to an improvement in operating margin to 9 percent from 8.8 percent in 2024.
This was despite the challenge posed by increases in National Insurance costs during the period.
The net assets of Superdrug on 27 December 2025 were £471.2m (up from £439.8m in 2024), with total assets of £1,207.3m (£1,176.7m in 2024) and total liabilities of £736.1m (£736.8m in 2024).
The Company maintained a strong cash position, closing the period with £235.1m (£200.6m in 2024). This was driven by an increase in operating profit and lower stock holding at the end of the financial period.
The British Retail Consortium had reported an overall decline in the UK high street footfall compared with 2024, but the health and beauty sector was among the few categories to deliver year-on-year sales growth.
